Kangying Li

Title: Innovations by Inventor Kangying Li

Introduction

Kangying Li is a notable inventor based in Tianjin, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of crystalline forms of important compounds. With a total of 2 patents, his work has the potential to impact the treatment of various diseases.

Latest Patents

Kangying Li's latest patents include innovative processes and formulations. One of his key inventions is the development of crystalline forms of Acalabrutinib. This invention provides specific crystalline forms, including Acalabrutinib Form APO-I, a co-crystal of Acalabrutinib and urea; APO-II, a co-crystal of Acalabrutinib and nicotinamide; APO-III, a co-crystal of Acalabrutinib and L-sorbitol; APO-IV, a crystalline form of Acalabrutinib; and APO-V, a co-crystal of Acalabrutinib and urea. Additionally, he has developed processes for the preparation of Ribociclib and its intermediates, which are crucial for the synthesis of this important compound.

Career Highlights

Kangying Li is associated with Apotex Inc., a leading pharmaceutical company known for its commitment to quality and innovation. His work at Apotex has allowed him to focus on the development of new pharmaceutical formulations and processes that can enhance drug efficacy and safety.

Collaborations

Kangying Li has collaborated with several talented individuals in his field, including Wancheng Guo and Fabio E S Souza. These collaborations have fostered a productive environment for innovation and have contributed to the advancement of their shared research goals.

Conclusion

Kangying Li's contributions to the pharmaceutical industry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in drug development and formulation.